Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 62Glioblastoma 52Lung Neoplasms 49Breast Neoplasms 46Prostatic Neoplasms 39Head and Neck Neoplasms 38Squamous Cell Carcinoma of Head and Neck 33Esophageal Neoplasms 30Brain Neoplasms 28Lymphoma 27Gliosarcoma 27Rectal Neoplasms 24Hodgkin Disease 24Pancreatic Neoplasms 22Adenocarcinoma Of Esophagus 22Central Nervous System Neoplasms 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Neoplasms 20Lymphoma, Non-Hodgkin 17Leukemia 17Glioma 17Burkitt Lymphoma 16Sarcoma 15Lymphoma, Large B-Cell, Diffuse 15Lymphoma, Follicular 14Carcinoma, Squamous Cell 14Colorectal Neoplasms 13Astrocytoma 13Neoplasm Metastasis 12Melanoma 12

Interventions

temsirolimus 1ganitumab 1efineptakin alfa 1Vinorelbine 1Vincristine 1Sirolimus 1Receptor Protein-Tyrosine Kinases 1Radiotherapy 1Radiation 1Irinotecan 1Dasatinib 1Dactinomycin 1Cyclophosphamide 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Rhabdomyosarcoma, Alveolar × Radiotherapy × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡